Brief--Semarion raises $3.8m to scale cell screening platform

UK biotech Semarion has secured $3.8 million (£2.9 million) to expand manufacturing and commercial reach of its cell-based screening technology, as it moves to convert early pharma interest into broader adoption.

The Cambridge spin-out said the round was led by Parkwalk, with backing from The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group and Start Codon.

Funds will support scale-up of the SemaCyte platform, which enables adherent cells to be handled as barcoded, assay-ready reagents. The company is also expanding its field application support team as pilot programs advance toward commercial rollout.

The technology is already being used by several global pharma companies, including top 10 players, with early-stage collaborations progressing into wider deployment.

Semarion’s platform targets a persistent bottleneck in drug discovery, where adherent cell models are difficult to automate and standardize, limiting throughput and reproducibility in screening workflows.

By integrating with existing lab systems and automation platforms, the company is positioning SemaCyte as a practical upgrade rather than a disruptive overhaul, aligning with industry demand for scalable, data-rich cell-based assays.